Recent Updates
Recently added Catalysts
VNDA Negative Sentiment

Vanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential Information

Tuesday, May 2, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Vanda Pharmaceuticals Inc. has initiated legal action against the federal government, claiming that the FDA improperly shared confidential information from its drug master files with generic manufacturers during their review process. The company alleges this misappropriation constitutes an 'uncompensated taking' of its trade secrets related to its products HETLIOZ® and Fanapt®. Filed in the United States Court of Federal Claims, Vanda seeks economic damages as a result of these actions.
Price reaction · baseline $6.43 (2023-05-01 close) · hit after-hours · 2 other VNDA headline(s) in the window, move may be shared
day 0 close
-0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Vanda Pharmaceuticals is actively protecting its trade secrets.
  • The lawsuit highlights the importance of intellectual property in biopharma.

CONCERNS & RISKS

  • Vanda alleges that confidential information was misappropriated by the FDA.
  • The lawsuit indicates potential legal and financial complications for Vanda.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+121%
120-day peak, hindsight
Typical move
19.9%
average across 7 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
Imsidolimab
Phase 2 · Palmoplantar Pustulosis

Full Press Release Details

WASHINGTON, May 2, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced its action against the federal government for the uncompensated taking and misuse of Vanda's trade secrets and confidential information. Vanda alleges that the U.S. Food and Drug Administration (FDA) improperly provided confidential details from Vanda's drug master files for its products, HETLIOZ® and Fanapt®, to generic drug manufacturers during the FDA's review of the manufacturers' Abbreviated New Drug Applications. The action was filed in the United States Court of Federal Claims and seeks an award of economic damages. A copy of the complaint can be found here (Vanda Pharmaceuticals Inc. v. USA, case no. 1:23-cv-00629-AOB).
About Vanda Pharmaceuticals Inc.
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.

Frequently Asked Questions

What did Vanda Pharmaceuticals announce on May 2, 2023?

Vanda Pharmaceuticals announced a lawsuit against the federal government over trade secret violations.

Which agency is accused of misusing Vanda's information?

The U.S. Food and Drug Administration (FDA) is accused of improperly sharing Vanda's details.

What products are involved in Vanda's lawsuit?

The products involved are HETLIOZ® and Fanapt®.

Where was the lawsuit filed by Vanda Pharmaceuticals?

The lawsuit was filed in the United States Court of Federal Claims.

What is Vanda seeking through this legal action?

Vanda is seeking economic damages from the federal government.

ShareAdd on Google
Tags: VNDA Viatris Investor Conferences Healthcare Vanda Pharmaceuticals FDA trade secrets HETLIOZ
Last updated: May 2, 2023

Biotech snapshot

Cash runway
$170M liquidity · $10M/mo burn
~16 mo
Low dilution risk
Lead asset
ImsidolimabPhase 2
Palmoplantar Pustulosis →

Catalyst track record

+121%
best trade around VNDA's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for VNDA.

See every catalyst's timing & PoA →